Na+/H+ exchanger activity is increased in doxorubicin‐resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Multidrug resistant (MDR) tumor cells exhibit an altered pH gradient across different cell compartments, which favors a reduced intracellular accumulation of antineoplastic drugs and a decreased therapeutic effect. In our study, we have observed that the activity and expression of Na+/H+ exchanger (NHE), which is involved in the homeostasis of intracellular pH (pH i), are increased in doxorubicin‐resistant (HT29‐dx) human colon carcinoma cells in comparison with doxorubicin‐sensitive HT29 cells. The pH i was significantly higher in HT29‐dx cells, which accumulated less doxorubicin than HT29 cells. The NHE inhibitor 5‐(N‐ethyl‐N‐isopropyl)amiloride (EIPA) significantly reduced the pH i value and increased the intracellular accumulation of doxorubicin in both cell populations: in the presence of EIPA HT29‐dx cells accumulated as much drug as control HT29 cells. On the other hand, monensin, a Na+/H+ ionophore mimicking NHE activation, and phorbol 12‐myristate 13‐acetate (PMA), which stimulates NHE, significantly increased the pH i and decreased the drug accumulation in HT29 cells to values similar to those observed in control HT29‐dx cells. EIPA potentiated the cytotoxic effect of doxorubicin in HT29 cells, and made HT29‐dx cells as sensitive to the cytotoxic effect of the drug as control HT29 cells. Instead, PMA and monensin made HT29 cells as insensitive to doxorubicin as HT29‐dx cells. These results suggest that in MDR cells the higher cytosolic pH is likely to decrease drug accumulation, and that such resistance can be reverted by inhibiting the NHE activity. This result opens the possibility to revert MDR with the clinical use of NHE inhibitors. © 2005 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · cited 4×
“' 2005 Wiley-Liss, Inc. Key words: multidrug resistance; Naþ/Hþ exchanger; colon carcinoma; doxorubicin Multidrug resistance (MDR) includes the numerous strategies by which tumor cells can elude the cytotoxic effect of chemotherapeutic agents and develop cross-resistance to a broad spectrum of drugs.1 Decreased accumu…”
BackgroundInfluential
Cited by
Dysregulated pH: a perfect storm for cancer progression
Webb, B. A., Chimenti, M., Jacobson, M. P., & Barber, D. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3110 · Cited by 2,237
Drug Resistance and Cellular Adaptation to Tumor Acidic pH Microenvironment
Wojtkowiak, J. W., Verduzco, D., Schramm, K. J., & Gillies, R. J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200292c · Cited by 566
The SLC9A-C Mammalian Na+/H+Exchanger Family: Molecules, Mechanisms, and Physiology
Pedersen, S. F., & Counillon, L. (2019) · Physiological Reviews · doi:10.1152/physrev.00028.2018 · Cited by 183
Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance
Belisario, D. C., Kopecka, J., Pasino, M., Akman, M., De Smaele, E., Donadelli, M., & Riganti, C. (2020) · Cells · doi:10.3390/cells9122598 · Cited by 133
Castella, B., Kopecka, J., Sciancalepore, P., Mandili, G., Foglietta, M., Mitro, N., Caruso, D., Novelli, F., Riganti, C., & Massaia, M. (2017) · Nature Communications · doi:10.1038/ncomms15663 · Cited by 82
Self-citationLucien, F., Pelletier, P.-P., Lavoie, R. R., Lacroix, J.-M., Roy, S., Parent, J.-L., Arsenault, D., Harper, K., & Dubois, C. M. (2017) · Nature Communications · doi:10.1038/ncomms15884 · Cited by 66
Metadata
- Authors
- Miraglia, E., Viarisio, D., Riganti, C., Costamagna, C., Ghigo, D., & Bosia, A.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2005-02-23
- Volume
- 115
- Issue
- 6
- Pages
- 924-929
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2030139214
- Cited by
- 86
- References
- 1
- FWCI
- 0.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.